The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside

Drug Resistance Updates

Volumn 17, Issue 3, 2014, Pages 37-50

  Seyedmousavi, Seyedmojtaba ^a,b   Mouton, Johan W ^a,b   Melchers, Willem J G ^a   Brüggemann, Roger J M ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aspergillus fumigatus; Azole resistance; Invasive aspergillosis; Management; Posaconazole; Voriconazole

Indexed keywords

FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT;

AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; DRUG EFFICACY; DRUG MECHANISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TREATMENT INDICATION; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; TRANSLATIONAL RESEARCH; TRENDS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, FUNGAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTATION; TRANSLATIONAL MEDICAL RESEARCH; TRIAZOLES; VORICONAZOLE;

EID: 84909639404     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.06.001     Document Type: Article

References (114)

1. AbuTarif, M.A., Krishna, G., Statkevich, P., 2010. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr. Med. Res. Opin. 26, 397-405.
2. AFST-EUCAST, 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14, 982-984.
3. AFST-EUCAST, 2013. EUCAST Definitions of Clinical Breakpoints and Epidemiological Cut-off Values. European Committee on Antimicrobial Susceptibility Testing.
4. Alanio, A., Sitterle, E., Liance, M., Farrugia, C., Foulet, F., Botterel, F., Hicheri, Y., Cordonnier, C., Costa, J.M., Bretagne, S., 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66, 371-374.
5. Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2008. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52, 1244-1251.
6. Andes, D., 2004. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist. Update 7, 185-194.
7. Andes, D., Pascual, A., Marchetti, O., 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53, 24-34.
8. Arendrup, M.C., Mavridou, E., Mortensen, K.L., Snelders, E., Frimodt-Moller, N., Khan, H., Melchers, W.J., Verweij, P.E., 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLOS ONE 5, e10080.
9. Arendrup, M.C., Cuenca-Estrella, M., Lass-Florl, C., Hope, W.W.T, European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility, 2012a. EUCAST technical note on Aspergillus and amphotericin B itraconazole, and posaconazole. Clin. Microbiol. Infect. 18, E248-E250.
10. Arendrup, M.C., Jensen, R.H., Grif, K., Skov, M., Pressler, T., Johansen, H.K., Lass-Florl, C., 2012b. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J. Infect. Dis. 206, 981-985.
11. Arendrup, M.C., Cuenca-Estrella, M., Lass-Florl, C., Hope, W.W., 2013. Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist. Update 16, 81-95.
12. Balajee, S.A., Gribskov, J.L., Hanley, E., Nickle, D., Marr, K.A., 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4, 625-632.
13. Bellete, B., Raberin, H., Morel, J., Flori, P., Hafid, J., Manhsung, R.T., 2010. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48, 197-200.
14. Bruggemann, R.J., Blijlevens, N.M., Burger, D.M., Franke, B., Troke, P.F., Donnelly, J.P., 2010a. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J. Antimicrob. Chemother. 65, 107-113.
15. Bruggemann, R.J., van Luin, M., Colbers, E.P., van den Dungen, M.W., Pharo, C., Schouwenberg, B.J., Burger, D.M., 2010b. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J. Antimicrob. Chemother. 65, 2188-2194.
16. Bueid, A., Howard, S.J., Moore, C.B., Richardson, M.D., Harrison, E., Bowyer, P., Denning, D.W., 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65, 2116-2118.
17. Buied, A., Moore, C.B., Denning, D.W., Bowyer, P., 2012. High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J. Antimicrob. Chemother. 68, 512-514.
18. Buied, A., Moore, C.B., Denning, D.W., Bowyer, P., 2013. High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J. Antimicrob. Chemother. 68, 512-514.
19. Camps, S.M., Dutilh, B.E., Arendrup, M.C., Rijs, A.J., Snelders, E., Huynen, M.A., Verweij, P.E., Melchers, W.J., 2012a. Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLOS ONE 7, e50034.
20. Camps, S.M., van der Linden, J.W., Li, Y., Kuijper, E.J., van Dissel, J.T., Verweij, P.E., Melchers, W.J., 2012b. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob. Agents Chemother. 56, 10-16.
21. Chowdhary, A., Kathuria, S., Xu, J., Meis, J.F., 2013. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 9, e1003633.
22. Chowdhary, A., Sharma, C., Kathuria, S., Hagen, F., Meis, J.F., 2014. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J. Antimicrob. Chemother. 69, 555-557.
23. Chen, J., Li, H., Li, R., Bu, D., Wan, Z., 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55 (1), 31-37.
24. CLSI, 2008. Reference Method for Broth Dilution Antifungal SusceptibilityTesting of Filamentous Fungi; Approved standard, 2nd ed. Clinical and Laboratory Standards Institute, Wane, PA, CLSI Document. M38-A2.
25. Cornely, O.A., Maertens, J., Winston, D.J., Perfect, J., Ullmann, A.J., Walsh, T.J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.T., Petrini, M., Hardalo, C., Suresh, R., Angulo-Gonzalez, D., 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348-359.
26. Cornely, O.A., Haider, S., Grigg, A., van Iersel, M., Caceres, M., Hepler, D., Waskin, H., Kartsonis, N., Robertson, M.N., 2013. Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) IV in patients (Pts) at risk for invasive fungal infection (IFI). In: American Society for Microbiology. 53rd ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy), Denver, CO, p. A-292.
27. Courtney, R., Radwanski, E., Lim, J., Laughlin, M., 2004. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 48, 804-808.
28. da Silva Ferreira, M.E., Capellaro, J.L., dos Reis Marques, E., Malavazi, I., Perlin, D., Park, S., Anderson, J.B., Colombo, A.L., Arthington-Skaggs, B.A., Goldman, M.H., Goldman, G.H., 2004. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob. Agents Chemother. 48, 4405-4413.
29. De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E., Calandra, T., Pappas, P.G., Maertens, J., Lortholary, O., Kauffman, C.A., Denning, D.W., Patterson, T.F., Maschmeyer, G., Bille, J., Dismukes, W.E., Herbrecht, R., Hope, W.W., Kibbler, C.C., Kullberg, B.J., Marr, K.A., Munoz, P., Odds, F.C., Perfect, J.R., Restrepo, A., Ruhnke, M., Segal, B.H., Sobel, J.D., Sorrell, T.C., Viscoli, C., Wingard, J.R., Zaoutis, T., Bennett, J.E., R. European Organization for, G. Treatment of Cancer/Invasive Fungal Infections Cooperative, A. National Institute of, and G. Infectious Diseases Mycoses Study Group Consensus, 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813-1821.
30. Denning, D.W., Perlin, D.S., 2011. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol. 6, 1229-1232.
31. Diaz-Guerra, T.M., Mellado, E., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47, 1120-1124.
32. EMA, 2012a. European Public Assessment Report (EPAR) for Noxafil. European Medicines Agency.
33. EMA, 2012b. European Public Assessment Report (EPAR) for Vfend. European Medicines Agency.
34. Espinel-Ingroff, A., Diekema, D.J., Fothergill, A., Johnson, E., Pelaez, T., Pfaller, M.A., Rinaldi, M.G., Canton, E., Turnidge, J., 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48, 3251-3257.
35. Finlay, G.J., Baguley, B.C., 2000. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother. Pharmacol. 45, 417-422.
36. Fraczek, M.G., Bromley, M., Buied, A., Moore, C.B., Rajendran, R., Rautemaa, R., Ramage, G., Denning, D.W., Bowyer, P., 2013. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 68, 1486-1496.
37. Garcia-Effron, G., Dilger, A., Alcazar-Fuoli, L., Park, S., Mellado, E., Perlin, D.S., 2008. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J. Clin. Microbiol. 46 (4), 1200-1206.
38. Geiser, D.M., Klich, M.A., Frisvad, J.C., Peterson, S.W., Varga, J., Samson, R.A., 2007. The current status of species recognition and identification in Aspergillus. Stud. Mycol. 59, 1-10.
39. Gerber, J., Chomicki, J., Brandsberg, J.W., Jones, R., Hammerman, K.J., 1973. Pulmonary aspergillosis caused by Aspergillus fischeri var. spinosus: report of a case and value of serologic studies. Am. J. Clin. Pathol. 60, 861-866.
40. Gollapudy, R., Ajmani, S., Kulkarni, S.A., 2004. Modeling and interactions of Aspergillus fumigatus lanosterol 14-alpha demethylase 'A' with azole antifungals. Bioorg. Med. Chem. 12, 2937-2950.
41. Groll, A.H., Gea-Banacloche, J.C., Glasmacher, A., Just-Nuebling, G., Maschmeyer, G., Walsh, T.J., 2003. Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. North Am. 17, 159-191, ix.
42. Guarro, J., Kallas, E.G., Godoy, P., Karenina, A., Gene, J., Stchigel, A., Colombo, A.L., 2002. Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil. Emerg. Infect. Dis. 8, 989-991.
43. Guinea, J., Pelaez, T., Recio, S., Torres-Narbona, M., Bouza, E., 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52, 1396-1400.
44. Hamprecht, A., Buchheidt, D., Vehreschild, J.J., Cornely, O.A., Spiess, B., Plum, G., Halbsguth, T.V., Kutsch, N., Stippel, D., Kahl, P., Persigehl, T., Steinbach, A., Bos, B., Hallek, M., Vehreschild, M.J., 2012. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill. 17, 20262.
45. Hedayati, M.T., Pasqualotto, A.C., Warn, P.A., Bowyer, P., Denning, D.W., 2007. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153, 1677-1692.
46. Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., Kern, W.V., Marr, K.A., Ribaud, P., Lortholary, O., Sylvester, R., Rubin, R.H., Wingard, J.R., Stark, P., Durand, C., Caillot, D., Thiel, E., Chandrasekar, P.H., Hodges, M.R., Schlamm, H.T., Troke, P.F., de Pauw, B., 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415.
47. Hodiamont, C.J., Dolman, K.M., Ten Berge, I.J., Melchers, W.J., Verweij, P.E., Pajkrt, D., 2009. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med. Mycol. 47, 217-220.
48. Hope, W.W., 2012. Population pharmacokinetics of voriconazole in adults. Antimicrob. Agents Chemother. 56, 526-531.
49. Hope, W.W., Cuenca-Estrella, M., Lass-Florl, C., Arendrup, M.C.T., European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility, 2013. EUCAST technical note on voriconazole and Aspergillus spp. Clin. Microbiol. Infect. 19, E278-E280.
50. Howard, S.J., Cerar, D., Anderson, M.J., Albarrag, A., Fisher, M.C., Pasqualotto, A.C., Laverdiere, M., Arendrup, M.C., Perlin, D.S., Denning, D.W., 2009. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15, 1068-1076.
51. Howard, S.J., Lestner, J.M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., Majithiya, J.B., Warn, P.A., Hope, W.W., 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203, 1324-1332.
52. Jarv, H., Lehtmaa, J., Summerbell, R.C., Hoekstra, E.S., Samson, R.A., Naaber, P., 2004. Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary Aspergillosis. J. Clin. Microbiol. 42, 925-928.
53. Jeans, A.R., Howard, S.J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Majithiya, J.B., Lass-Florl, C., Cuenca-Estrella, M., Arendrup, M.C., Warn, P.A., Hope, W.W., 2012. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J. Infect. Dis. 206, 442-452.
54. Klaassen, C.H., de Valk, H.A., Curfs-Breuker, I.M., Meis, J.F., 2010. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J. Antimicrob. Chemother. 65, 901-905.
55. Krishna, G., Moton, A., Ma, L., Medlock, M.M., McLeod, J., 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53, 958-966.
56. Krishna, G., Ma, L., Martinho, M., O'Mara, E., 2012a. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob. Agents Chemother. 56, 4196-4201.
57. Krishna, G., Ma, L., Martinho, M., Preston, R.A., O'Mara, E., 2012b. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J. Antimicrob. Chemother. 67, 2725-2730.
58. Kuipers, S., Bruggemann, R.J., de Sevaux, R.G., Heesakkers, J.P., Melchers, W.J., Mouton, J.W., Verweij, P.E., 2011. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob. Agents Chemother. 55, 3564-3566.
59. Latge, J.P., 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12, 310-350.
60. Lepak, A.J., Marchillo, K., Vanhecker, J., Andes, D.R., 2013a. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob. Agents Chemother. 57, 5438-5447.
61. Lepak, A.J., Marchillo, K., Vanhecker, J., Andes, D.R., 2013b. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 57, 579-585.
62. Liu, W., Sun, Y., Chen, W., Liu, W., Wan, Z., Bu, D., Li, R., 2012. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob. Agents Chemother. 56, 2598-2603.
63. Maertens, J., Cornely, O.A., Ullmann, A., Heinz, W., Krishna, G., Caceres, M., Kartsonis, N., Waskin, H., Paton, B., Robertson, M.N., 2012. Phase 1B study of the pharmacokinetics (PK) and safety of posaconazole (POS) IV in patients (Pts) at risk for invasive fungal infection (IFI). In: Microbiology, A.S.F. (Ed.), 52nd ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy), San Francisco, CA., p. 1946.
64. Mavridou, E., Bruggemann, R.J., Melchers, W.J., Mouton, J.W., Verweij, P.E., 2010a. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54, 860-865.
65. Mavridou, E., Bruggemann, R.J., Melchers, W.J., Verweij, P.E., Mouton, J.W., 2010b. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54, 4758-4764.
66. Meletiadis, J., Mavridou, E., Melchers, W.J., Mouton, J.W., Verweij, P.E., 2012. Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob. Agents Chemother. 56 (5), 2524-2529.
67. Mellado, E., Diaz-Guerra, T.M., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2001. Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39, 2431-2438.
68. Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48, 2747-2750.
69. Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Melchers, W.J., Verweij, P.E., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51, 1897-1904.
70. Mellado, E., De La Camara, R., Buendia, B., Rodriguez-Tudela, J.L., Cuenca-Estrella, M., 2013. Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. Rev. Iberoam. Micol. 30, 64-68.
71. Mohr, J., Johnson, M., Cooper, T., Lewis, J.S., Ostrosky-Zeichner, L., 2008. Current options in antifungal pharmacotherapy. Pharmacotherapy 28, 614-645.
72. Mouton, J.W., Dudley, M.N., Cars, O., Derendorf, H., Drusano, G.L., 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55, 601-607.
73. Nascimento, A.M., Goldman, G.H., Park, S., Marras, S.A., Delmas, G., Oza, U., Lolans, K., Dudley, M.N., Mann, P.A., Perlin, D.S., 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47, 1719-1726.
74. Natesan, S.K., Lamichchane, A.K., Swaminathan, S., Wu, W., 2013. Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus. Diagn. Microbiol. Infect. Dis. 76, 458-463.
75. Pascual, A., Csajka, C., Buclin, T., Bolay, S., Bille, J., Calandra, T., Marchetti, O., 2012. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin. Infect. Dis. 55, 381-390.
76. Peterson, S.W., Varga, J., Frisvad, J.C., Samson, R.A., 2008. Phylogeny and Subgeneric Taxonomy of Aspergillus. Wageningen Academic Publishers, Wageningen.
77. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N., 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46, 1032-1037.
78. Pfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., Diekema, D., 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. 49, 586-590.
79. Purkins, L., Wood, N., Greenhalgh, K., Allen, M.J., Oliver, S.D., 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56 (1 (Suppl.)), 10-16.
80. Rath, P.M., Buchheidt, D., Spiess, B., Arfanis, E., Buer, J., Steinmann, J., 2012. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob. Agents Chemother. 56, 6060-6061.
81. Rodriguez-Tudela, J.L., Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Monzon, A., Cuenca-Estrella, M., 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52, 2468-2472.
82. Roffey, S.J., Cole, S., Comby, P., Gibson, D., Jezequel, S.G., Nedderman, A.N., Smith, D.A., Walker, D.K., Wood, N., 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31, 731-741.
83. Schwartz, S., Ruhnke, M., Ribaud, P., Corey, L., Driscoll, T., Cornely, O.A., Schuler, U., Lutsar, I., Troke, P., Thiel, E., 2005. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106, 2641-2645.
84. Seyedmousavi, S., Bruggemann, R.J., Melchers, W.J., Rijs, A.J., Verweij, P.E., Mouton, J.W., 2013a. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J. Antimicrob. Chemother. 68, 385-393.
85. Seyedmousavi, S., Hashemi, S.J., Zibafar, E., Zoll, J., Hedayati, M.T., Mouton, J.W., Melchers, W.J., Verweij, P.E., 2013b. Azole-resistant Aspergillus fumigatus, Iran. Emerg. Infect. Dis. 19, 832-834.
86. Seyedmousavi, S., Melchers, W.J., Mouton, J.W., Verweij, P.E., 2013c. Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 57, 1866-1871.
87. Seyedmousavi, S., Meletiadis, J., Melchers, W.J., Rijs, A.J., Mouton, J.W., Verweij, P.E., 2013d. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob. Agents Chemother. 57, 796-803.
88. Seyedmousavi, S., Mouton, J.W., Verweij, P.E., Bruggemann, R.J., 2013e. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev. Anti Infect. Ther. 11, 931-941.
89. Sheng, C., Zhang, W., Zhang, M., Song, Y., Ji, H., Zhu, J., Yao, J., Yu, J., Yang, S., Zhou, Y., Zhu, J., Lu, J., 2004. Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions. J. Biomol. Struct. Dyn. 22, 91-99.
90. Siopi, M., Mavridou, E., Mouton, J.W., Verweij, P.E., Zerva, L., Meletiadis, J., 2014. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. J. Antimicrob. Chemother. 69 (6), 1611-1619.
91. Smith, D.A., Di, L., Kerns, E.H., 2010. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev. 9, 929-939.
92. Snelders, E., van der Lee, H.A., Kuijpers, J., Rijs, A.J., Varga, J., Samson, R.A., Mellado, E., Donders, A.R., Melchers, W.J., Verweij, P.E., 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5, e219.
93. Snelders, E., Huis In't Veld, R.A., Rijs, A.J., Kema, G.H., Melchers, W.J., Verweij, P.E., 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75, 4053-4057.
94. Snelders, E., Karawajczyk, A., Schaftenaar, G., Verweij, P.E., Melchers, W.J., 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob. Agents Chemother. 54, 2425-2430.
95. Snelders, E., Camps, S.M., Karawajczyk, A., Schaftenaar, G., Kema, G.H., van der Lee, H.A., Klaassen, C.H., Melchers, W.J., Verweij, P.E., 2012. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLOS ONE 7, e31801.
96. Ullmann, A.J., Cornely, O.A., Burchardt, A., Hachem, R., Kontoyiannis, D.P., Topelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., Corcoran, G., Raad, I., 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50, 658-666.
97. Ullmann, A.J., Lipton, J.H., Vesole, D.H., Chandrasekar, P., Langston, A., Tarantolo, S.R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., Pedicone, L., Patino, H., Durrant, S., 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335-347.
98. van der Linden, J.W., Jansen, R.R., Bresters, D., Visser, C.E., Geerlings, S.E., Kuijper, E.J., Melchers, W.J., Verweij, P.E., 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48, 1111-1113.
99. van der Linden, J.W., Warris, A., Verweij, P.E., 2011a. Aspergillus species intrinsically resistant to antifungal agents. Med. Mycol. 49 (Suppl 1), S82-S89.
100. van der Linden, J.W., Snelders, E., Kampinga, G.A., Rijnders, B.J., Mattsson, E., Debets-Ossenkopp, Y.J., Kuijper, E.J., Van Tiel, F.H., Melchers, W.J., Verweij, P.E., 2011b. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17, 1846-1854.
101. van der Linden, J.W., Camps, S.M., Kampinga, G.A., Arends, J.P., Debets-Ossenkopp, Y.J., Haas, P.J., Rijnders, B.J., Kuijper, E.J., van Tiel, F.H., Varga, J., Karawajczyk, A., Zoll, J., Melchers, W.J., Verweij, P.E., 2013. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin. Infect. Dis. 57, 513-520.
102. van Ingen, J., van der Lee, H.A.L., Rijs, A.J.M.M., Zoll, J., Leenstra, T., Melchers, W.J.G., Verweij, P.E., 2014. Azole and non-azole MIC distributions of wild type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands (submitted for publication).
103. van Leer-Buter, C., Takes, R.P., Hebeda, K.M., Melchers, W.J., Verweij, P.E., 2007. Aspergillosis and a misleading sensitivity result. Lancet 370, 102.
104. Vermeulen, E., Lagrou, K., Verweij, P.E., 2013. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr. Opin. Infect. Dis. 26, 493-500.
105. Verweij, P.E., Mellado, E., Melchers, W.J., 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356, 1481-1483.
106. Verweij, P.E., Howard, S.J., Melchers, W.J., Denning, D.W., 2009a. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Update 12, 141-147.
107. Verweij, P.E., Snelders, E., Kema, G.H., Mellado, E., Melchers, W.J., 2009b. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9, 789-795.
108. Walsh, T.J., Raad, I., Patterson, T.F., Chandrasekar, P., Donowitz, G.R., Graybill, R., Greene, R.E., Hachem, R., Hadley, S., Herbrecht, R., Langston, A., Louie, A., Ribaud, P., Segal, B.H., Stevens, D.A., van Burik, J.A., White, C.S., Corcoran, G., Gogate, J., Krishna, G., Pedicone, L., Hardalo, C., Perfect, J.R., 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44, 2-12.
109. Walsh, T.J., Anaissie, E.J., Denning, D.W., Herbrecht, R., Kontoyiannis, D.P., Marr, K.A., Morrison, V.A., Segal, B.H., Steinbach, W.J., Stevens, D.A., van Burik, J.A., Wingard, J.R., Patterson, T.F., 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327-360.
110. Warrilow, A.G., Martel, C.M., Parker, J.E., Melo, N., Lamb, D.C., Nes, W.D., Kelly, D.E., Kelly, S.L., 2010a. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob. Agents Chemother. 54, 4235-4245.
111. Warrilow, A.G., Melo, N., Martel, C.M., Parker, J.E., Nes, W.D., Kelly, S.L., Kelly, D.E., 2010b. Expression purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. Antimicrob. Agents Chemother. 54, 4225-4234.
112. Warris, A., Weemaes, C.M., Verweij, P.E., 2002. Multidrug resistance in Aspergillus fumigatus. N. Engl. J. Med. 347, 2173-2174.
113. Xiao, L., Madison, V., Chau, A.S., Loebenberg, D., Palermo, R.E., McNicholas, P.M., 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48, 568-574.
114. Zeitlinger, M.A., Derendorf, H., Mouton, J.W., Cars, O., Craig, W.A., Andes, D., Theuretzbacher, U., 2011. Protein binding: do we ever learn? Antimicrob. Agents Chemother. 55, 3067-3074.